Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchXiannuoxinXiannuoxin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Xiannuoxin for COVID-19
2 studies from 48 scientists
1,027 patients in 1 country
One study shows statistically significant improvement.
COVID-19 Xiannuoxin studies. Feb 2024. c19early.org
0 0.5 1 1.5+ All studies 37% Recovery 37% Viral clearance 38% RCTs 37% Early 37% Favorsxiannuoxin Favorscontrol
Xiannuoxin is a combination of simnotrelvir and ritonavir. Simnotrelvir is a first generation SARS-CoV-2 3CL protease inhibitor Bischof. Ritonavir is a HIV drug used to boost the levels of simnotrelvir in the body by inhibiting its metabolism. Recent:
Jung
Lu
Wang
Cao.
Xiannuoxin has been officially adopted in 1 country. Submit updates/corrections.
Feb 26
Covid Analysis Xiannuoxin for COVID-19: real-time meta analysis of 2 studies
Meta analysis using the most serious outcome reported shows 37% [-46‑73%] lower risk, without reaching statistical significance. Currently all studies are RCTs. One study shows statistically significant improvement. Studies to ..
Jan 15
Jung et al., Toxics, doi:10.3390/toxics12010073 Ritonavir Has Reproductive Toxicity Depending on Disrupting PI3K/PDK1/AKT Signaling Pathway
In vitro study on boar spermatozoa showing that the HIV drug ritonavir (part of paxlovid and xiannuoxin) causes reproductive toxicity by disrupting the PI3K/PDK1/AKT signaling pathway. Ritonavir suppressed sperm functions including motili..
Dec 31
2023
Yang et al., European Journal of Pharmaceutical Sciences, doi:10.1016/j.ejps.2023.106598 A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects
RCT 72 healthy subjects evaluating safety, tolerability, and pharmacokinetics of simnotrelvir (SSD8432, SIM0417), a 3CL protease inhibitor, alone or co-administered with ritonavir at various single and multiple ascending oral doses and un..
Dec 31
2023
Bischof, E., Aging and disease, doi:10.14336/AD.2023.0318 Mitigating COVID-19 Mortality and Morbidity in China's Aging Population: A Focus on Available Medications and Future Developments
Review focusing on 3CL protease inhibitors. First generation inhibitors like paxlovid and simnotrelvir require boosting with ritonavir, which can cause drug-drug interactions and other issues. Second generation inhibitors like ensitrelvir..
Oct 13
2023
Jiang et al., Nature Communications, doi:10.1038/s41467-023-42102-y Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir
In Vitro and mouse study showing the development and preclinical evaluation of the SARS-CoV-2 3C-like protease (3CLpro) inhibitor simnotrelvir (SSD8432, SIM0417, part of xiannuoxin) as an orally bioavailable COVID-19 therapeutic agent...
Sep 30
2023
Wang et al., The Lancet Regional Health - Western Pacific, doi:10.1016/j.lanwpc.2023.100835 Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial
68% faster recovery (p=0.06) and 38% improved viral clearance (p=0.11). RCT 32 adults with asymptomatic, mild or moderate COVID-19 in China showing greater viral load reduction and faster time to symptom alleviation with xuannuoxin (simnotrelvir plus ritonavir) compared to placebo. All adverse events were mild.
Jul 31
2023
Lu et al., Progress in Pharmaceutical Sciences, doi:10.20053/j.issn1001-5094.2023.07.002 XIANNUOXIN®: China’s First Anti-SARS-CoV-2 Drug Targeting 3C-like Protease
Review of the development and approval of Xiannuoxin, the first domestic anti-COVID-19 drug targeting the 3C-like protease (3CLpro) approved in China. Xiannuoxin was jointly developed by Simcere Pharmaceutical Group, Shanghai Institute of..
Jan 29
2023
Cao et al., New England Journal of Medicine, doi:10.1056/NEJMoa2301425 (press release 1/29/2023) Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
17% faster recovery (p<0.0001). RCT 1,208 outpatients with mild-moderate COVID-19 in China, showing faster symptom resolution (by 35.8 hours) and faster viral clearance with xiannuoxin (simnotrelvir plus ritonavir) twice daily for 5 days.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit